Search Results - (Author, Cooperation:M. H. Rasmussen)

2014-08-01

Nature Publishing Group (NPG)

0028-0836

1476-4687

Biology

Chemistry and Pharmacology

Medicine

Natural Sciences in General

Physics

Alleles ; Cell Transformation, Neoplastic/genetics/pathology ; Colorectal Neoplasms/*genetics/pathology ; DNA Methylation ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/*genetics ; Genes, Neoplasm ; Genome-Wide Association Study ; Genotype ; Germ-Line Mutation/genetics ; Humans ; Intestinal Mucosa/cytology/metabolism/pathology ; Quantitative Trait Loci/genetics ; Regulatory Sequences, Nucleic Acid/*genetics ; Sequence Analysis, RNA ; Transcription Factors/metabolism ; Transcriptome/genetics

1751-8369

Blackwell Publishing Journal Backfiles 1879-2005

Geography

Geosciences

Age determinations for rock samples collected by Fridtjof Nansen during his trans-Arctic expedition from 1893-1896 have yielded additional information on the tectonic chronology of the Arctic Basin. The data suggest pulses of volcanic activity in the Frans Josef Land Archipelago with approximate averages of 120 ma and 135 ma. These ages are consistent with postulated opening dates for the western Arctic and thus suggest that initial volcanism affected the entire Arctic margin.

Electronic Resource

1751-8369

Blackwell Publishing Journal Backfiles 1879-2005

Geography

Geosciences

New aeromagnetic data, K-Ar age determinations of dredged marine igneous rocks, as well as other geophysical evidence have shed light on the chronology, nature and evolution of the northern Iceland Plateau. Correspondence between seismic refraction profiles taken on the Jan Mayen Ridge and westward through Jan Mayen Island, suppressed aeromagnetic anomalies, earthquake surface wave studies, and ages of dredged igneous rocks suggest these strata may form an extended region of thickened crust, possibly of Caledonian age, extending westward toward the Kolbeinsey Ridge and northwest to the south wall of the Jan Mayen Fracture Zone.

Electronic Resource

1432-0428

Key words Intranasal insulin administration ; absorption enhancers ; metabolic control ; subcutaneous insulin administration.

Springer Online Journal Archives 1860-2000

Medicine

Summary To evaluate metabolic control and safety parameters (hypoglycaemia frequency and nasal mucosa physiology), 31 insulin-dependent diabetic patients were treated with intranasal insulin at mealtimes for 1 month and with subcutaneous fast-acting insulin at meals for another month in an open, cross-over randomized trial. During both treatment periods the patients were treated with intermediate-acting insulin at bedtime. Six of the patients were withdrawn from the study during intranasal insulin therapy due to metabolic dysregulation. Serum insulin concentrations increased more rapidly and decreased more quickly during intranasal as compared with subcutaneous insulin administration. Metabolic control deteriorated, as assessed by haemoglobin A1c concentrations, slightly but significantly after intranasal as compared with subcutaneous insulin therapy. The bioavailability of intranasally applied insulin was low, since intranasal insulin doses were approximately 20 times higher than subcutaneous doses. The frequency of hypoglycaemia was similar during intranasal and subcutaneous insulin therapy, and nasal mucosa physiology was unaffected after intranasal insulin. We conclude that due to low bioavailability and to a high rate of therapeutic failure, intranasal insulin treatment is not a realistic alternative to subcutaneous insulin injections at the present time. [Diabetologia (1995) 38: 680–684]

Electronic Resource

1432-0428

Intranasal insulin administration ; absorption enhancers ; metabolic control ; subcutaneous insulin administration

Springer Online Journal Archives 1860-2000

Medicine

Summary To evaluate metabolic control and safety parameters (hypoglycaemia frequency and nasal mucosa physiology), 31 insulin-dependent diabetic patients were treated with intranasal insulin at mealtimes for 1 month and with subcutaneous fast-acting insulin at meals for another month in an open, crossover randomized trial. During both treatment periods the patients were treated with intermediate-acting insulin at bedtime. Six of the patients were withdrawn from the study during intranasal insulin therapy due to metabolic dysregulation. Serum insulin concentrations increased more rapidly and decreased more quickly during intranasal as compared with subcutaneous insulin administration. Metabolic control deteriorated, as assessed by haemoglobin A1c concentrations, slightly but significantly after intranasal as compared with subcutaneous insulin therapy. The bioavailability of intranasally applied insulin was low, since intranasal insulin doses were approximately 20 times higher than subcutaneous doses. The frequency of hypoglycaemia was similar during intranasal and subcutaneous insulin therapy, and nasal mucosa physiology was unaffected after intranasal insulin. We conclude that due to low bioavailability and to a high rate of therapeutic failure, intranasal insulin treatment is not a realistic alternative to subcutaneous insulin injections at the present time.

Electronic Resource